Search
for
Sort by
Research 91–120 of 584
- Alopecia Areata: Case report and review of pathophysiology and treatment with Jak inhibitors
- Role of topical tofacitinib in autoimmune skin disorders: An expert opinion
- Upadacitinib in the treatment of a patient with the triad of atopic dermatitis, vitiligo, and alopecia areata: a case report and literature review
- Upadacitinib in dermatologic therapy: Emerging evidence and expanding indications
- Baricitinib for the Treatment of Moderate-to-Severe Alopecia Areata
- Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis
- Use of Jak Inhibitors in the Treatment of Alopecia Areata
- The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm
- Role of janus kinase inhibitors in the treatment of alopecia areata
- A novel therapeutic paradigm for patients with extensive alopecia areata
- New drugs under investigation for the treatment of alopecias
- Successful Treatment of Refractory Alopecia Areata Universalis and Psoriatic Arthritis, But Not of Plaque Psoriasis with Tofacitinib in a Young Woman
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
- Episodic Neuropathic-Like Musculoskeletal Pain Associated With Ritlecitinib Therapy in Alopecia Universalis: A Case Report
- Alopecia areata: A clinical review of the changing landscape with Janus kinase inhibitors
- Use of oral Janus kinase inhibitors for the treatment of severe alopecia areata: narrative review and real-world experience
- Significant improvement with ivarmacitinib after suboptimal response to tofacitinib in severe alopecia areata: a case report and literature review
- Pharmacotherapy of alopecia areata
- Hair for the Long Haul: Alopecia Areata Cases and Considerations
- Dermatologic Comorbidities Associated with Atopic Dermatitis Towards a Shared Therapeutical Approach: A Narrative Review
- Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review
- Perspectives of Chinese Adult Patients with Alopecia Areata on Janus Kinase Inhibitors Therapy: A Qualitative Analysis Based on Social Media Platforms
- The efficacy and safety of JAK inhibitors for alopecia areata: A systematic review and meta-analysis of prospective studies
- Discovery of a novel and highly selective JAK3 inhibitor as a potent hair growth promoter
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
- JAK Inhibitors for Treatment of Alopecia Areata
- SYK inhibitor entospletinib prevents ocular and skin GVHD in mice
- Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A promising therapy for the treatment of alopecia areata: A case report of six patients
- Natural Melanogenesis Inhibitor, Antioxidant, and Collagen Biosynthesis Stimulator of Phytochemicals in Rice Bran and Husk Extracts from Purple Glutinous Rice (Oryza sativa L. cv. Pieisu 1 CMU) for Cosmetic Application
- Hair Growth Effect of Emulsion Extracted Brevilin A, a JAK3 Inhibitor, from Centipeda minima